Medicare Part D May Lose Long-Term Luster For Pharma
Executive Summary
The Medicare drug benefit's positive effect on the pharmaceutical business could be short-lived, Wharton Business School Senior Fellow Stan Bernard suggested at the Pharmaceutical Marketing Congress in Philadelphia
You may also be interested in...
Pfizer Medicare Rx Outreach Gains Momentum With Share Card Network
Pfizer is using its network of more than 17,000 community groups established during its "U-Share Card" program to begin implementing the company's Medicare prescription drug benefit education program, VP-Community Advocacy Forest Harper said
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials